Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “BUTYRATES”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 577 records · Page 32Linked to original sources
PubMedDate not supplied

[Application of new radiopharmaceutical "Sodium 11c-butyrate" and positron emission tomography in patients with coronary artery disease].

UNLABELLED: The aim of this study was to examine the diagnostic value of Sodium 11C-Butyrate (11C-Butyrate) in assessing perfusion and oxydative metabolism in patients with coronary artery disease (CAD). 41 patients (39 male and 9 female, mean age 48 +/- 11) with CAD were investigated. PET-scans were performed twice: at 2-7 min and 25-31 min after i.v. injection of 250-400 MBq 11C-Butyrate. Regional perfusion was evaluated by the uptake of radioactivity in the myocardium at the first scan, intensity of beta-oxidation--by decreasing the uptake level at the second scan. RESULTS: Myocardium of the left ventricle was good visualized at the first scan. It was demonstrated fast elimination of radioactivity in segments with normal oxidative metabolism of 11C-Butyrate at the second scan. Fixed defects were seen in the scar segments both at first and second scans. Decreased uptake of 11C-Butyrate at the first scan and diminished rate of agent elimination caused by depressed beta-oxidation at the second scan were revealed in ischemic segments. CONCLUSION: Application of PET with 11C-Butyrate in patients with CAD allows estimate hypoperfused segments, evaluate heart oxidative metabolism and provides differential diagnosis of scar and ischemia.

Butyrates↗
PubMed1989

[Determination of volatile fatty acids in the blood plasma of cattle before and after an infusion of propionate and butyrate].

Before and after infusion of propionate and butyrate the concentrations of volatile fatty acids (VFA) in the blood of heifers were determined by gas chromatography, in order to indicate activity and regulation of the carbohydrate metabolism. 14 heifers were loaded after food deprivation with intravenous infusions of propionate and butyrate. Concentrations of acetate, propionate, isobutyrate, butyrate, and valerate were measured in blood samples which were taken later on. The methods used for clearance and extraction as well as for gas chromatographic analysis are described. Retention times and blood concentrations are given for each VFA. Concentrations prior to infusion were for: acetate 10.14 +/- 2.51 microliters/ml; propionate 0.42 +/- 0.35 microliters/ml; iso-butyrate 3.72 +/- 1.37 microliters/ml; butyrate 3.44 +/- 0.68 microliters/ml blood plasma. The concentrations of the infused VFA showed a 100 (butyrate) to 1000 (propionate) fold increase followed by a subsequent decrease to the initial values. These investigations on the profile of VFA elucidated criteria of the energy metabolism.

Animals↗
PubMed1998

Butyrate attenuates BCLX(L) expression in human fibroblasts and acts in synergy with ionizing radiation to induce apoptosis.

Ionizing radiation is a poor inducer of apoptosis in many cell types. In this study we investigated what effect the differentiation agent butyrate had on the cellular levels of the apoptosis regulators BCL2, BCLX(L) and BAX and on radiation-induced apoptosis. It was found that butyrate significantly lowered the level of the apoptosis antagonist BCLX(L) in a time- and dose-dependent manner in diploid human fibroblasts. The reduction of the level of BCLX(L) protein by butyrate correlated with an increased induction of apoptosis in cells irradiated with ionizing radiation. Butyrate also acted in synergy with ultraviolet (UV) light and cisplatin to induce apoptosis in human fibroblasts. Radiosensitization was obtained when butyrate was added before and/or after irradiation, although the combination of treatment both before and after irradiation was the most effective. Our results suggest that butyrate acts in synergy with ionizing radiation, UV light and cisplatin to induce apoptosis, perhaps by lowering the level of the apoptosis antagonist BCLX(L) in cells.

Apoptosis↗
PubMed1998

Differential regulation of A gamma and G gamma fetal hemoglobin mRNA levels by hydroxyurea and butyrate.

In clinical studies, both hydroxyurea and butyrate increase fetal hemoglobin expression and ameliorate the symptoms of sickle cell anemia. However, comparative studies of the effects of hydroxyurea and butyrate on the expression of the individual fetal hemoglobin genes, A gamma and G gamma, have not been performed. The present study reports the effects of hydroxyurea and butyrate on steady-state A gamma and G gamma mRNA levels in K562 cells. Because the high degree of homology between the A gamma and G gamma cDNA sequences precludes the use of large cDNA probes for detection of individual fetal hemoglobin gene products, we investigated the specificity of two 20-base oligonucleotide probes synthesized from the region of greatest sequence diversity between these genes. Hybridization experiments demonstrated that the A gamma oligonucleotide probe was specific for A gamma DNA and RNA sequences and the G gamma oligonucleotide probe was specific for G gamma DNA and RNA sequences. These oligonucleotide probes detected both A gamma and G gamma mRNAs in K562 cells. In K562 cells treated with 2 mM sodium butyrate for 168 hours, the G gamma mRNA level increased 3.6-fold, whereas the A gamma mRNA level was not significantly different from untreated cells. Similar results were obtained when K562 cells were treated with 80 microM hydroxyurea. The G gamma mRNA level increased 2.3-fold at 168 hours, whereas the A gamma mRNA level did not change. The above results demonstrate that both butyrate and hydroxyurea selectively increase G gamma expression. Selective regulation of individual fetal hemoglobin genes is also seen in human development, where approximately 70% of the total fetal hemoglobin in the fetus is G gamma. Therefore, understanding the mechanisms by which butyrate and hydroxyurea differentially regulate fetal hemoglobin gene expression may provide insights into the developmental regulation of hemoglobin expression as well as the mechanisms of action of pharmacological agents currently being used to treat sickle cell disease.

Butyrates↗
PubMed1998

Sodium butyrate induces retinoblastoma protein dephosphorylation, p16 expression and growth arrest of colon cancer cells.

Sodium butyrate causes alteration of colon cancer cell morphology and biology towards that of a more differentiated phenotype. The retinoblastoma gene encodes a nuclear phosphoprotein (pRb) present in a wide range of human cancer cell lines including colon cancer cell lines. pRB is synthesized throughout the cell cycle and phosphorylated in a phase specific manner: the predominant proteins in G0/G1 are the unphosphorylated species (110 kD) whereas phosphorylated pRb (112-114 kD) are in S and G2. 110 kD pRb binds transcription factors and prevents transcription of responsive genes such as the gene for thymidine kinase, which are expressed in late G1. The precise mechanisms controlling cell arrest are unknown, but recent data suggest that cyclin-dependent kinase inhibitors such as p16 may play a role. The aim of the present study was to assess the effect of sodium butyrate on cell cycle staging, thymidine kinase activity, phosphorylation of the pRb protein and expression of p16. We show that sodium butyrate treatment induces differentiation of LS174T colon cancer cells, inhibits thymidine kinase activity concomitantly with induction of pRb dephosphorylation, p16 transcription and cell cycle arrest at G0/G1. Initial dephosphorylation was observed 24 h after treatment of LS174T cells with sodium butyrate, whereas complete shift to the dephosphorylated form was observed 3 days after treatment. Induction of pRb dephosphorylation by sodium butyrate preceded inhibition of growth and the specific cell cycle arrest. RNase protection assay with a p16 specific riboprobe showed undetectable levels in proliferating cells to several fold increase in differentiated colonocytes. In conclusion, the results provide evidence for a specific cellular mechanism of butyrate induced growth arrest and differentiation of a colon cancer cell line.

Alkaline Phosphatase↗
PubMed1982

Transaminative metabolism of alpha-amino-n-butyrate in rats.

alpha-Amino-n-butyrate metabolism was studied in a rt tissue homogenate system using L-[1-14C] alpha-amino-n-butyrate. Transamination was found to be the major route in the liver for the metabolism of L-alpha-amino-n-butyrate based on 44.8 mumoles/g/h of [1-14-C] alpha-ketobutyrate formed in the presence of pyruvate versus 1.2 mumoles/g/h without pyruvate. The pH optimum for the reaction was 9.2. The abilities of other alpha-keto acids to act as a cosubstrate relative to pyruvate were (%): pyruvate, 100; alpha-ketobutyrate, 80; alpha-keto-gamma-methiolbutyrate, 15; phenylpyruvate, 14; alpha-ketoglutarate, p-hydroxyphenylpyruvate and the alpha-keto analogs of the branched-chain amino acids, all less than 10. The apparent Km for alpha-amino-n-butyrate in the liver homogenate was approximately 38 mM and the Km for pyruvate was 5 mM. Kidney was found to have about twice the activity as liver. Activities in brain, heart, diaphragm, muscle and small intestine were negligible. With the exception of serine, no other added amino acids could compete effectively with alpha-amino-n-butyrate for transamination in the rat liver homogenate system. Activity in rat liver was inhibited by aminooxyacetic acid and cycloserine. These results indicate that alpha-amino-n-butyrate is metabolized primarily by a transaminase reaction with pyruvate which occurs almost exclusively in liver and kidney.

4-Aminobutyrate Transaminase↗
PubMed1997

Butyrate- but not TGFbeta1-induced apoptosis of colorectal adenoma cells is associated with increased expression of the differentiation markers E-cadherin and alkaline phosphatase.

Sodium butyrate and transforming growth factor beta (TGFbeta1) are growth inhibitory to colonic adenoma cell lines. Butyrate induces apoptosis, whereas in some adenoma cell lines, TGFbeta1 can be growth inhibitory without apoptosis. In this report, we show that the adenoma cell line PC/BH/C1 undergoes apoptosis in response to TGFbeta1. Butyrate induced cell death is preceded by the induction of two markers of colonic differentiation--alkaline phosphatase (ALP) activity and E-cadherin protein expression. However, TGFbeta1-induced apoptosis was not accompanied by induction of these differentiation markers. It is possible that the apoptosis induced by TGFbeta1 in the adenoma cell line PC/BH/C1 is due to conflicting signals, as downregulation of c-myc protein in response to TGFbeta1 occurs only slowly in this cell line. Development of resistance to TGFbeta1 in colonic tumours may involve two separate stages--resistance to growth inhibition and resistance to TGFbeta1-induced apoptosis. Our results indicate that sodium butyrate induces apoptosis via differentiation, but TGFbeta1 induces apoptosis by a differentiation-independent mechanism. As for butyrate, the induction of E-cadherin expression is a potentially important chemopreventative action, since increased E-cadherin expression has been correlated with decreased metastatic potential. This is the first report of induction of E-cadherin by a naturally occurring factor in the diet. Butyrate may reduce tumour growth and invasion, not only as a result of the induction of apoptosis, but also through increased expression of E-cadherin.

Journal Article↗
PubMed1992

Reciprocal isomerization of butyrate and isobutyrate by the strictly anaerobic bacterium strain WoG13 and methanogenic isobutyrate degradation by a defined triculture.

Isomerization of butyrate and isobutyrate was investigated with the recently isolated strictly anaerobic bacterium strain WoG13 which ferments glutarate to butyrate, isobutyrate, CO(2), and small amounts of acetate. Dense cell suspensions converted butyrate to isobutyrate and isobutyrate to butyrate. C-nuclear magnetic resonance experiments proved that this isomerization was accomplished by migration of the carboxyl group to the adjacent carbon atom. In cell extracts, both butyrate and isobutyrate were activated to their coenzyme A (CoA) esters by acyl-CoA:acetate CoA-transferases. The reciprocal rearrangement of butyryl-CoA and isobutyryl-CoA was catalyzed by a butyryl-CoA:isobutyryl-CoA mutase which depended strictly on the presence of coenzyme B(12). Isobutyrate was completely degraded via butyrate to acetate and methane by a defined triculture of strain WoG13, Syntrophomonas wolfei, and Methanospirillum hungatei.

Journal Article↗
PubMed1991

Differential effects of sodium butyrate and hexamethylene bisacetamide on growth and secretion of cultured human endocrine tumor cells.

Advanced gastrointestinal endocrine tumors respond poorly to conventional chemotherapy. In this study we examined the effects of two agents that promote cellular differentiation, sodium butyrate and hexamethylene bisacetamide, on the in vitro growth and secretory responses of a human pancreatic carcinoid (BON) and human gastrinoma (PT-2 and PT-SM) cell lines that have been established in our laboratory. We found that both sodium butyrate and hexamethylene bisacetamide strongly inhibited growth of BON, PT-2, and PT-SM cells. With continuous exposure of BON cells to sodium butyrate (2 mmol/L), the doubling time was prolonged, from 60 hours in controls to 156 hours, and saturation density was reduced to 28% that of controls. Hexamethylene bisacetamide (4 mmol/L) reduced saturation density to 37% that of controls in BON cells and prolonged the doubling time, from 60 hours to 103 hours. Antiproliferative effects of similar magnitudes were observed in the gastrinoma cell lines. In contrast, differential effects were produced on amine biosynthesis in BON cells; sodium butyrate stimulated levels of 5-hydroxytryptamine in the cells, whereas hexamethylene bisacetamide caused a profound dose-dependent inhibition of amine biosynthesis. The significant antiproliferative activity of sodium butyrate and hexamethylene bisacetamide and the inhibitory effects of hexamethylene bisacetamide on amine biosynthesis warrant evaluation of these agents or analogues for treatment of metastatic carcinoid and gastrinoma.

5-Hydroxytryptophan↗
PubMed1983

Modulation of K562 cells with sodium butyrate. Association of impaired NK susceptibility with sialic acid and analysis of other parameters.

Neuraminidase treatment of parental and butyrate-induced K562 tumor cells was associated with an increase in natural killer (NK) susceptibility of these target cells. The degree of enhancement with neuraminidase was significantly greater for the NK-resistant (NRR) butyrate-differentiated K562 cells so that the relative difference between the parental NK-sensitive (NKS) K562 line and its induced NKR variants, in terms of NK sensitivity, was no longer five- or six-fold but only two-fold. The predominant reason for the altered NK susceptibilities of the target cells after neuraminidase treatment was an increase in the target-cell-binding ability of these cells as assessed by a direct conjugate-forming cell assay using Percoll-enriched NK cells and cold target competition assays. The enhancement did not appear to be due simply to an increased membrane-membrane attraction caused by a reduction of net negative cell surface charges since protamine sulphate, a positively charged molecule, had no effect on NK activity. Compared with the NKS parental K562 tumor cells, the NKR butyrate-induced cells had 3.6- to 4.0-fold higher sialo-transferase activities and were associated with significantly greater amounts of cell surface sialic acid detected both in sialyl glycoproteins (2.2- to 2.9-fold higher) and particularly within ganglioside extracts (6.2- to 13.6-fold higher). In conformity with the marked neuraminidase enhancement of NK-mediated cytolysis of the butyrate-induced targets, these NKR cells were associated with significantly enhanced levels of neuraminidase-accessible sialic acid compared to the NKS parental K562 cell line. Other parameters such as sensitivity to superoxide radicals, intrinsic superoxide dismutase levels, altered membrane repair mechanisms and transferrin competition, were not significantly different between the NKS and NKR target phenotypes. Sugar inhibition studies demonstrated an enhanced inhibition against the butyrate-induced cells with a variety of neutral sugars. The degree of inhibition with phosphorylated sugars was comparable between the parental and induced K562 tumor target cells and is consistent with our previous findings showing that these hexose phosphates may be inhibiting cytolysis at a step independent of target-cell recognition.

Butyrates↗
PubMed1991

Derivatives of butyric acid as potential anti-neoplastic agents.

A novel derivative of butyric acid, pivalyloxymethyl butyrate (AN-9) has been shown, in vitro, to: (a) induce cytodifferentiation and inhibit the proliferation of leukemic cells; (b) inhibit the growth and formation of Lewis lung carcinoma colonies in semi-solid agar. AN-9 affect cells at about 10-fold lower concentration and at a faster rate than does butyric acid. The pivalyloxymethyl esters of propionic, isobutyric and valeric acids do not elicit effects similar to those of AN-9, while the isobutyryloxymethyl butyrate does, which strongly suggests that the activity of AN-9 stems from intracellular metabolic degradation of the pro-drug to butyric acid. In vivo, AN-9, increased the survival of mice in Lewis lung carcinoma primary cancer model and significantly decreased the number of lung lesions of the animals inoculated with highly metastatic cells, but did not affect their life span. Acute LD50 studies have shown that AN-9 possesses low toxicity. These results suggest that AN-9 is a potential anti-neoplastic agent as well as a tool for investigation of the differentiation induction mechanism.

Animals↗
PubMed1994

Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL-60 leukemic cell line.

A butyric acid pro-drug, pivaloyloxymethyl butyrate, AN-9, developed in our laboratory, was previously shown to act as a differentiation-inducing and an anti-cancer agent. In this study we have shown that both AN-9 and butyric acid caused a transient hyperacetylation of histones, which returned to basal levels after 6 and 12 hr, respectively. This activity precedes the induction of differentiation elicited by both agents. AN-9 induced acetylation of histones at a concentration one order of magnitude lower than butyric acid. Pre-treatment of the cells with esterase(s) inhibitors diminished the ability of AN-9 to inhibit proliferation and induce differentiation. The above suggests that the intracellular release of butyric acid fragment, from the pro-drug, is catalyzed by cellular esterase(s).

Acetylation↗
PubMed1995

Among 17 inducers of differentiation only sodium butyrate causes a permanent down-regulation of c-myc in Burkitt's lymphoma.

De-regulation of c-myc by chromosomal translocation is one crucial step for the development of Burkitt's lymphoma. The de-regulation is caused through juxtaposition of c-myc with one of the 3 immunoglobulin loci. We have reported earlier that treatment of Burkitt's lymphoma cells with n-butyrate causes transcriptional down-regulation of c-myc expression. Because of the possible therapeutic implication of this result, we looked for other compounds which, on the one hand, might be applicable in vivo and, on the other hand, might cause down-regulation of c-myc expression in Burkitt's lymphoma cells. Since n-butyrate is known to induce differentiation, we have examined other differentiation inducers of different chemical nature for their ability to reduce c-myc expression in Burkitt's lymphoma cells. Many of the substances tested caused down-regulation of c-myc expression, which, however, was transient except for n-butyrate. Three types of compounds proved to be particularly active: polar planar compounds (e.g., dimethylsulfoxide), heterocyclic compounds (e.g., hypoxanthine), and short-chain fatty acids (e.g., n-butyric acid). The action of n-butyrate on c-myc suppression was exceptional not only in not being transient, but also in being allele-specific: it down-regulated the translocated allele without affecting the normal one. Medium transfer experiments revealed that neither degradation of the active compound nor an intracellular resistance mechanism can fully account for the reversibility of c-myc down-regulation after treatment with the transiently acting polar planar compounds.

Alleles↗
PubMed1987

Truncation does not abrogate transcriptional downregulation of the c-myc gene by sodium butyrate in Burkitt's lymphoma cells.

We have examined the effect of sodium butyrate, a potent inducer of differentiation in various cell systems, on the steady state RNA level and transcriptional activity of the c-myc gene in Burkitt's lymphoma cells. Following sodium butyrate treatment a rapid decrease of c-myc RNA was observed in all Burkitt's lymphoma cell lines studied, irrespective of the type of translocation, the location of the breakpoint relative to c-myc or of the association with EBV. Since cellular genes induced by interferon are suspected to play a role in c-myc regulation we have studied transcription of the 2-5A synthetase gene in sodium butyrate-treated Burkitt's lymphoma cells. Transcriptional activity and steady state mRNA levels of the 2-5A synthetase gene were induced by sodium butyrate. The time course of induction excluded, however, that the decrease of c-myc RNA is caused by induction of the 2-5A synthetase/RNase L endonuclease system. The reduction of c-myc RNA is caused, at least in part, by a reduced transcription rate, as shown by nuclear run-on analysis. The fact that sodium butyrate is capable of downregulating a truncated c-myc gene indicates that an important target site of transcriptional regulation is located outside the region encompassing the upstream regulatory sequences, the dual promoters and the leader region.

2',5'-Oligoadenylate Synthetase↗
PubMed1995

Induction of heat labile alkaline phosphatase by butyrate in differentiating endometrial cells.

The addition of 2 mM sodium butyrate to monolayers enhances differentiation of Ishikawa endometrial cells. Cells from this cell line have been shown to enlarge and lift off the dish into dome structures over a period of 24-48 h in response to a factor in fetal bovine serum (FBS) [Fleming, 1995 J Cell Biochem in press]. When butyrate is added to monolayers, together with FBS, three- to fourfold higher numbers of differentiated structures, domes and predomes, can be counted. It had previously been shown [Holinka et al., 1986b] that estradiol induces heat stable placental alkaline phosphatase in Ishikawa cells. The addition of butyrate, on the other hand, results in a significant increase in levels of a heat labile alkaline phosphatase isozyme. The heat labile isozyme is also increased to some extent in cells stimulated to differentiate in response to FBS in the absence of butyrate. Differential inhibition by homoarginine and phenylalanine indicates that butyrate is inducing the liver-bone kidney isozyme that is found in endometrial glands in vivo.

Alkaline Phosphatase↗
PubMed1993

Regulation of C-fos expression by sodium butyrate in the human colon carcinoma cell line Caco-2.

We used sodium butyrate to modify the differentiation and growth properties of the Caco-2 colon adenocarcinoma cell line and considered c-fos proto-oncogene expression as a potential target. C-fos is induced by butyric acid very rapidly at a post-transcriptional level and is stimulated transcriptionally at later times. This transcriptional induction does not result in an increase in steady-state mRNA levels. We show by transient transfection assays that the ATF-CRE binding site located between -63 and -54 relative to the c-fos transcriptional start site is a target for butyrate-induced fos transcription. Furthermore, gel retardation assays show an increase in CRE binding activity in cells treated with butyrate. These results demonstrate that butyrate can affect specific transcription factors important for cell growth and differentiation at multiple levels of regulation.

Activating Transcription Factors↗
PubMed1994

Butyrate induced apoptosis in lymphoid cells preceded by transient over-expression of HSP70 mRNA.

In addition to inducing differentiation in several cell types sodium butyrate is cytotoxic to lymphoid cells and causes apoptosis in HL-60 cells. We report here that butyrate treatment of the Burkitt's lymphoma cell line BL-30 causes cell death by apoptosis, as established by nuclear changes and DNA fragmentation. The kinetics of induction of apoptosis by butyrate revealed a considerably delayed response in comparison to that observed with heat treatment. At 4 h after heat (43.5 degrees C) exposure, 50% of the cells were undergoing apoptosis whereas that level of apoptosis was only reached after 16 h of treatment with butyrate (5 mM). Apoptosis induced by both treatments was accompanied by a marked increase in hsp70 mRNA. The maximum response in mRNA preceded a rapid onset of apoptosis in both cases, and the response was transient. There was a corresponding increase in the level of hsp70 protein after exposure to both heat and butyrate which coincided with the pattern of increase in mRNA but protein levels remained high during the onset of apoptosis. The results obtained here provide further evidence for a relationship between differentiation and apoptosis.

Apoptosis↗
PubMed1996

Direct inhibition of the expression of cyclin D1 gene by sodium butyrate.

In the mouse fibroblasts BP-A31 as well as in the human epidermoid carcinoma cells KB-3-1, both cyclin D1 mRNA and protein contents decreased rapidly during incubation with sodium butyrate. The decrease of cyclin D1 mRNA was not prevented by cycloheximide indicating that protein synthesis is not required for the inhibition of the expression of cyclin D1 gene by sodium butyrate. The 973 bp region upstream of the human cyclin D1 gene conferred inhibition of the expression of an indicator gene in transiently transfected cells. An 11 base-pair segment situated within this region, with a strong homology to the butyrate-response consensus element identified in butyrate-inducible promoters, also caused an inhibition of transcription under these conditions, indicating that cyclin D1 expression is inhibited by butyrate at the transcriptional level.

Animals↗